Auxilium Pharmaceuticals, Inc a specialty biopharmaceutical company, today announced financial results and operational highlights for the quarter ended September 30, 2010. For the third quarter of 2010, Auxilium reported net revenues of $53.6 million compared to net revenues of $42.1 millionin the third quarter of 2009. The net loss for the third quarter of 2010 was $(12.8) million, or $(0.27) per share, compared to a net loss of $(14.9) million, or $(0.35) per share, reported for the third quarter of 2009.
"In the third quarter, we continued to make advances with both of our marketed products. We saw a significant increase in the number of sites using XIAFLEX for the treatment of Dupuytren's contracture, which helped support the peer to peer discussions of XIAFLEX at the meeting of the American Society for Surgery of the Hand in October. We also finished preparation for the recent initiation of our XIAFLEX phase III global development program for the treatment of Peyronie's disease, a potential second indication for XIAFLEX," said Armando Anido, Chief Executive Officer and President of Auxilium. "Testim U.S. net revenue continued to grow with a 17.9% increase year over year in the third quarter, and we believe that the U.S. Food and Drug Administration's response to Abbott Laboratories' Citizen Petition on generic testosterone gel products is a significant, positive event for Testim."
No comments:
Post a Comment